Dry Eye Disease

Can someone take a look at the archives and figure out the first time I spouted off about the importance of treating the ocular surface preop and postop?

VILAMOURA, Portugal — At the European Society of Cataract and Refractive Surgeons winter meeting, Karl G. Stonecipher, MD, speaks about a new machine learning model for the diagnosis and treatment of dry eye.

Healio spoke with Leslie O’Dell, OD, FAAO, medical director and director of clinical research at Medical Optometry America in Shrewsbury, about research needs and upcoming treatment options for patients with dry eye disease.

How important is the nerve supply to the health of the cornea?

One of the biggest challenges in dry eye care has always been getting the primary eye care population interested in treating ocular surface disease.

Neuromodulation and neurostimulation are close cousins, but they are not the same thing.

Artificial tears have long been the first option for patients with dry eye disease, but they only offer a partial solution.

Here it is, at last, the official report of the (not very) momentous (non)randomized (un)controlled clinical trial of “Fauxstasis.”

Treatment-related serious adverse events in ocular safety, the primary endpoints in a 12-month safety clinical trial of reproxalap for the treatment of dry eye disease, were not observed, according to an Aldeyra Therapeutics press release.

Some eye care specialists may believe they do not have time have time to deal with ocular surface disease — that tackling dry eye disease is too time-consuming, complicated and confusing, potentially making them inefficient with patients.